CollPlant Biotechnologies Ltd (OPHI)
CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine enterprise operating across the United States, Canada, and Europe. The company primarily engages in the three-dimensional (3D) bioprinting of tissues and organs, alongside developing solutions for medical aesthetics. All of CollPlant's offerings are underpinned by its proprietary plant-based genetic engineering technology, which facilitates the production of recombinant type I human collagen. Its diverse product portfolio encompasses BioInks engineered for 3D tissue and organ fabrication; dermal and soft tissue fillers designed to diminish wrinkles; and innovative breast implants, both 3D bioprinted and injectable, aimed at promoting breast tissue regeneration. CollPlant also provides a 3D bioprinted regenerative soft tissue matrix. Specialized products include VergenixSTR, a soft tissue repair matrix targeting tendinopathy, and VergenixFG, an advanced wound care treatment for deep surgical incisions and persistent wounds such as diabetic, venous, and pressure ulcers, burns, and bedsores. The company maintains strategic collaboration agreements with numerous partners, including 3D Systems Corporation, CellInk (a BICO Group company), the Advanced Regenerative Manufacturing Institute, the RegenMed Development Organization, Israel's Technion Institute of Technology, AbbVie, and STEMCELL. Established in Rehovot, Israel, in 2004, the company was formerly known as CollPlant Holdings Ltd. before adopting its current name in June 2019.
Sector: Orthopedic, Prosthetic & Surgical Appliances & Supplies
Industry: Medical - Specialties
CollPlant Biotechnologies Ltd.
- 2.9%
- 35.6K
- 1.03
Float 1.25M · Signal8 dilution snapshot · Nov 3, 2026
The cost to borrow OPHI shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.
- No fails on record for 16–31 Oct 2026.
Latest short interest settlements (today's share basis)
| Date | Shares short |
|---|---|
| Oct 30, 2026 | 35.6K sh |
| Oct 15, 2026 | 52.7K sh |
| Sep 30, 2026 | 42.2K sh |
| Sep 15, 2026 | 52.2K sh |
| Aug 31, 2026 | 13.1K sh |
A stock split executed inside this window; every settlement plotted has been carried onto today’s share basis, so the line does not step at the split.
The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.
Too few published sessions to show a reading in context.
FINRA's weekly alternative trading system (dark pool) volume for OPHI: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.
As of the Oct 30, 2026 FINRA settlement, 35,612 OPHI shares were sold short (2.86% of a 1.25M-share float, 1.03 days to cover).